Divi’s Labs Stock Set for 15% Upside: Nuvama Reveals 3 Growth Drivers
India’s pharmaceutical sector has been in the spotlight for global investors, and one stock that continues to attract attention is Divi’s Laboratories. Recently, brokerage firm Nuvama Institutional Equities reaffirmed its ‘Buy’ rating on Divi’s Labs, setting a target price of ₹7,110. This implies an upside potential of nearly 15% from current levels, making the stock